ISRG's Growth Narrative Faces U.S. Slowdown and Rising Competition

What happened

On September 11, 2026, Intuitive Surgical executives acknowledged a recent deceleration in U.S. procedures and policy-related uncertainty affecting hospitals, while emphasizing continued global procedure growth. The company's Q2 2026 filing showed U.S. da Vinci procedure growth slowed to 12% year over year from 14%, and management attributed part of the weakness to the ACA subsidy expiration. Meanwhile, competitive threats intensified as Johnson & Johnson's OTTAVA received FDA market authorization and Medtronic's Hugo expanded urologic indications with pending general surgery and gynecology 510(k)s. The stock has de-rated sharply, falling from around $440 a year ago to $348.45, as investors shifted from expecting re-acceleration to demanding proof. Despite a strong installed base and 85% recurring revenue, the current valuation assumes a recovery that filings have not yet delivered.

Implication

The operating business remains excellent, but the market is now in 'show me' mode; without evidence of re-acceleration the stock likely remains range-bound with downside risk. Investors should monitor whether U.S. growth stabilizes outside bariatrics and whether China pressure eases, both required catalysts for a re-rating. The rise in leased placements to 54% of Q2 da Vinci systems is a warning sign that financing is masking weaker outright demand, and further increases would be negative. Competitive launches from J&J and Medtronic are unlikely to disrupt the installed base immediately but could pressure pricing and placement growth over 12-24 months. A better setup would be either a pullback to $320, where the margin of safety improves, or hard evidence that procedure growth and guidance are re-accelerating.

Thesis delta

The original thesis was that Intuitive's moat and recurring revenue justified premium valuation despite competition. However, the latest data and management commentary confirm U.S. procedure growth has stalled at 12% and policy headwinds are real, making re-acceleration less certain. The thesis shifts from 'buy on any dip' to 'wait for either a lower entry price or observable inflection in U.S. utilization and guidance.'